Journal of Neuro-Oncology

, Volume 89, Issue 1, pp 97–103

Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme

  • Angelique E. Sijben
  • John B. McIntyre
  • Gloria B. Roldán
  • Jacob C. Easaw
  • Elizabeth Yan
  • Peter A. Forsyth
  • Ian F. Parney
  • Anthony M. Magliocco
  • Hans Bernsen
  • J. Gregory Cairncross
Clinical-patient studies

DOI: 10.1007/s11060-008-9593-6

Cite this article as:
Sijben, A.E., McIntyre, J.B., Roldán, G.B. et al. J Neurooncol (2008) 89: 97. doi:10.1007/s11060-008-9593-6

Abstract

Introduction Elderly patients have glioblastomas (GBM) that are aggressive and poorly responsive to treatment. They are also prone to the side effects of treatment of GBM. Methods To shed light on the treatment of elderly patients with GBM, we reviewed the treatment toxicities and survival of patients 65 years of age or older who were treated with chemoradiotherapy, which is the new standard of care for GBM in younger patients. Results Thirty-nine patients at a single cancer center in Canada met the eligibility criteria for this retrospective study. Nineteen patients were treated initially with TMZ and radiotherapy and 20 others were treated with radiotherapy alone (only two had TMZ subsequently). Eight patients in the chemoradiotherapy group (42%) experienced Grade III or IV toxicity versus none in the radiotherapy group. The median overall survival in the chemoradiotherapy group was 8.5 months (range, 2.0–24.7 months) versus 5.2 months (range, 1.5–14.2 months) in the radiotherapy group, an apparent benefit which may have been due to an imbalance in age at diagnosis, extent of resection and performance status. In this series of GBM cases, methylation of the MGMT gene promoter was not associated with longer survival, either overall, or within the chemoradiotherapy treated subset. Conclusions Elderly patients with GBM treated with chemoradiotherapy can be expected to experience significant toxicity. Large randomized trials will be necessary to determine whether chemoradiotherapy prolongs the survival of elderly patients and whether MGMT promoter status predicts benefit from temozolomide in this subset of patients.

Keywords

ChemoradiotherapyElderly patientsGlioblastomaToxicity

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Angelique E. Sijben
    • 1
  • John B. McIntyre
    • 2
    • 3
    • 4
  • Gloria B. Roldán
    • 2
    • 4
    • 5
  • Jacob C. Easaw
    • 2
    • 4
  • Elizabeth Yan
    • 2
    • 4
  • Peter A. Forsyth
    • 2
    • 4
  • Ian F. Parney
    • 4
    • 5
  • Anthony M. Magliocco
    • 3
    • 4
  • Hans Bernsen
    • 1
  • J. Gregory Cairncross
    • 4
    • 5
  1. 1.Department of NeurologyCanisius Wilhelmina HospitalNijmegenThe Netherlands
  2. 2.Department of OncologyTom Baker Cancer CentreCalgaryCanada
  3. 3.Department of Pathology and Laboratory MedicineUniversity of CalgaryCalgaryCanada
  4. 4.Clark Smith Brain Tumor CenterCalgaryCanada
  5. 5.Department of Clinical NeurosciencesFoothills Medical Centre, University of CalgaryCalgaryCanada